GSK recalls 600,000 Ventolin Inhalers from US

GSK recalls 600,000 Ventolin Inhalers from US

Multinational pharmaceutical company, GlaxoSmithKline (GSK) has announced the recall of over 590,000 Salbutamol  (Ventolin) inhalers from the US market, saying there could be issues with the delivery technique.

The recall is for three lots of Ventolin HFA 200D inhalers with lot numbers 6ZP0003, 6ZP9944 and 6ZP9848.

The inhalers, according to reports,  have been distributed to hospitals, pharmacies, retailers and wholesalers in the United States.

“There is attainable risk that the affected inhalers could potentially not deliver the stated number of actuations,” according to GSK spokesman Juan Carlos Molina. “We continue to investigate the situation in order to identify the root lead to and implement appropriate corrective and preventative actions.”

The recall is not directed at individuals, but those with inhalers from the recalled lots have been advised to contact the company.

About author

You might also like

Health writers laud appointment of medical professionals as health ministers

Recommend priorities The Health Writers Association of Nigeria, (HEWAN), on Friday September 6, commended Presiden t Muhammadu Buhari for appointing two notable medical practitioners as health Ministers. A release signed

Bank commemorates World Cerebral Palsy Day

FBN Holdings Plc is demonstrating its commitment to support people living with disabilities in its through by organising an advocacy campaign for the World Cerebral Palsy Day.         

BREAKING NEWS 0 Comments

Depression tops list of ill health causes, new WHO estimates reveal

Over 300 million people now living with depression worldwide DG  calls for re-think on countries’ approach to mental health Depression increases risk of substance use disorders,  diabetes,  heart disease etc GENEVA

0 Comments

No Comments Yet!

You can be first to comment this post!

Leave a Reply